SCHEDULE 13D

The disclosure provided in Item 3 of the Original Schedule 13D is updated to include the following additional disclosure. The Reporting Person acquired the Securities (as defined below) in exchange for consideration in the amount of $3,000,000. The information set forth in Item 4 is incorporated by reference in its entirety into this Item 3.

The disclosure provided in Item 4 of the Original Schedule 13D is updated to include the following additional disclosure. On September 2, 2025, the Reporting Person entered into a Securities Purchase Agreement (the "Purchase Agreement") with the Issuer, pursuant to which it agreed to purchase from the Issuer (i) shares of the Issuer's Series H Convertible Preferred Stock (the "Series H Preferred Shares"), convertible into 600,000 shares of Common Stock at an initial conversion price of $5.00 per share, and (ii) warrants with a five-year term from November 14, 2025, the date that the Issuer's stockholders approved the issuance of more than 19.99% of the Issuer's outstanding shares of Common Stock in accordance with Nasdaq listing standards ("Stockholder Approval") to purchase up to 600,000 shares of Common Stock at an exercise price of $5.00 per share (the "Warrants"). Pursuant to the adjustment provisions in the Series H Preferred Shares and the Warrants, the conversion price of the Series H Preferred Shares and the exercise price of the Warrants subsequently adjusted from $5.00 per share to $3.3713 per share and the number of shares of Common Stock issuable to the Reporting Person upon conversion of the Series H Preferred Shares was adjusted proportionally to 889,865 and the number of Warrants was adjusted proportionally to 889,865. The Series H Preferred Shares and Warrants shall be referred to herein as the "Securities," and the Reporting Person's purchase thereof shall be referred to herein as the "Transaction." Pursuant to the Purchase Agreement, the Reporting Person has the right to participate in future sales of the Issuer's equity and equity-linked securities until the later of (x) the date the Series H Preferred Shares are no longer outstanding and (y) the Maturity Date of the Series H Preferred Shares (as defined in the Issuer's Certificate of Designations of Series H Convertible Preferred Stock (the "Certificate of Designations")). The Preferred Shares The terms of the Series H Preferred Shares are set forth in the Certificate of Designations, which the Issuer filed with the Secretary of State for the State of Delaware on September 4, 2025. The Series H Preferred Shares will be convertible into shares of Common Stock (the "Conversion Shares") at the election of the Reporting Person at any time at a conversion price of $3.3713 (the "Conversion Price"). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of shares of Common Stock, or securities convertible, exercisable or exchangeable for shares of Common Stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). Pursuant to the Certificate of Designations, the Reporting Person will be entitled to dividends of 7.0% per annum, compounded monthly, which will be payable in cash. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series H Preferred Shares will accrue dividends at the rate of 15% per annum. Upon conversion, the Reporting Person is also entitled to receive a dividend make-whole payment. The Reporting Person will be entitled to vote with holders of the Common Stock on as as-converted basis, with the number of votes to which the Reporting Person is entitled to be calculated assuming a conversion price of $3.3713 per share. The Issuer's ability to settle conversions and make dividend make-whole payments by issuing shares of Common Stock is subject to certain limitations set forth in the Certificate of Designations. The Certificate of Designations includes certain Triggering Events (as defined in the Certificate of Designations), including, among other things, the failure by the Issuer to file and maintain an effective registration statement covering the sale of the securities registrable pursuant to the Registration Rights Agreement (as defined below) and the failure by the Issuer to pay any amounts to the Reporting Person when due. In connection with a Triggering Event, the Reporting Person will be able to require the Issuer to redeem in cash any or all of its Series H Preferred Shares at a premium set forth in the Certificate of Designations. The Warrants The Warrants are exercisable for shares of Common Stock upon receipt of Stockholder Approval which was obtained on November 14, 2025, at an exercise price of $3.3713 per share and expire five years from the date of Stockholder Approval on November 14, 2030. The exercise price of each Warrant is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a "full ratchet" basis, in the event of any issuances of shares of Common Stock or securities convertible, exercisable or exchangeable for shares of Common Stock at a price below the then-applicable exercise price (subject to certain exceptions). Except as set forth in this Item 4, the Reporting Person does not have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities Act of 1933, as amended (the "Securities Act"). Registration Rights Agreement The Series H Preferred Shares, the shares of Common Stock issuable upon conversion of the Series H Preferred Shares (the "Conversion Shares"), the Warrants and the shares of Common Stock issuable upon exercise of the Warrants (the "Warrant Shares") have not been registered under the Securities Act. The Issuer and the Reporting Person entered into a Registration Rights Agreement (the "Registration Rights Agreement"), pursuant to which the Issuer was required to file a resale registration statement (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") to register for resale 200% of the Conversion Shares and the Warrant Shares within 30 calendar days after closing date of the Transaction, and to have such Registration Statement declared effective by the Effectiveness Date (as defined in the Registration Rights Agreement). The foregoing descriptions of the Purchase Agreement, the Certificate of Designations, the Warrants and the Registration Rights Agreement are qualified in their entirety by the full text of the Purchase Agreement, the Certificate of Designations, the form of Warrant and the Registration Rights Agreement, copies of which are filed as Exhibits 6, 7, 8 and 9, respectively, to this Amendment and incorporated herein by reference.

Item 5(a - c) of the Original Schedule 13D is hereby amended and supplemented as follows: See Items 7-13 of the cover pages of this Amendment and Item 2 of the Original Schedule 13D.

See Items 7-13 of the cover pages of this Amendment and Item 2 of the Original Schedule 13D.

Except as described in Items 3 and 4 of this Amendment, which descriptions are incorporated herein by reference, the Reporting Person has not effected any transactions in the Common Stock during the past 60 days.

6. Securities Purchase Agreement, dated September 2, 2025, by and among PharmaCyte Biotech, Inc. and TNF Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to the Reporting Person's Current Report on Form 8-K filed on September 5, 2025). https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_ex1001.htm 7. Form of Certificate of Designations of Series H Convertible Preferred Stock of TNF Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to the Reporting Person's Current Report on Form 8-K filed on September 5, 2025). https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_ex1002.htm 8. Form of Warrant of TNF Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.3 to the Reporting Person's Current Report on Form 8-K filed on September 5, 2025). https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_ex1003.htm 9. Registration Rights Agreement, dated September 2, 2025, by and among PharmaCyte Biotech, Inc. and TNF Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.5 to the Reporting Person's Current Report on Form 8-K filed on September 5, 2025). https://www.sec.gov/Archives/edgar/data/1157075/000168316824003796/pharmacyte_ex1005.htm